The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched the Global Radiopharmaceutical Trial Finder, an AI-powered platform aimed at facilitating the discovery of radiopharmaceutical clinical trials for researchers, clinicians, and patients. The platform, developed by Ancora.ai, allows users to quickly find relevant trials based on specific conditions, location, and eligibility criteria, utilizing real-time data from global registries. This initiative seeks to increase patient participation in clinical trials, which is currently low despite high interest. The Trial Finder is designed to enhance accessibility to nuclear medicine treatments, potentially improving outcomes for patients with cancer and other diseases. The tool is accessible at www.snmmi.org/TrialFinder.
Wed, 13 Aug 2025 03:45:00 GMT | News-Medical